Literature DB >> 2528469

Spontaneous recovery of streptozotocin diabetes in mice.

K Hartmann1, W Besch, H Zühlke.   

Abstract

With the aim of developing a model of experimental diabetes by which spontaneous recovery processes can be investigated, we used a lower (1) and a higher (2) dose of streptozotocin (SZ) to find out the lowest possible dose definitely inducing diabetes in mice through beta cell loss but preventing excessive damage to the endocrine pancreas which would exclude restoration processes. After application of SZ (1) to neonatal mice only male animals showed an overt diabetes in adult life. 70 percent of these mice had recovered 15 weeks after appearance of diabetes. Recovery was indicated by normalization of blood glucose, serum insulin, insulin secretion and biosynthesis of isolated pancreatic islets and a reenhancement of the pancreatic insulin content from lower than 10 to 30 percent of control values. After SZ (2) both sexes became hyperglycaemic, and the recovery rate was lower, but was increased by pregnancy in female mice. By means of this model it will be possible to investigate mechanisms and promoting factors of such restoration processes in more detail.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2528469     DOI: 10.1055/s-0029-1210861

Source DB:  PubMed          Journal:  Exp Clin Endocrinol        ISSN: 0232-7384


  8 in total

1.  PTEN controls β-cell regeneration in aged mice by regulating cell cycle inhibitor p16ink4a.

Authors:  Ni Zeng; Kai-Ting Yang; Jennifer-Ann Bayan; Lina He; Richa Aggarwal; Joseph W Stiles; Xiaogang Hou; Vivian Medina; Danny Abad; Beth M Palian; Ismail Al-Abdullah; Fouad Kandeel; Deborah L Johnson; Bangyan L Stiles
Journal:  Aging Cell       Date:  2013-08-06       Impact factor: 9.304

2.  Antibody Response to Serpin B13 Induces Adaptive Changes in Mouse Pancreatic Islets and Slows Down the Decline in the Residual Beta Cell Function in Children with Recent Onset of Type 1 Diabetes Mellitus.

Authors:  Yury Kryvalap; Chi-Wen Lo; Ekaterina Manuylova; Raman Baldzizhar; Nicholas Jospe; Jan Czyzyk
Journal:  J Biol Chem       Date:  2015-11-17       Impact factor: 5.157

3.  Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes.

Authors:  Bangyan L Stiles; Christine Kuralwalla-Martinez; Wei Guo; Caroline Gregorian; Ying Wang; Jide Tian; Mark A Magnuson; Hong Wu
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

4.  In vivo characterization of transplanted human embryonic stem cell-derived pancreatic endocrine islet cells.

Authors:  A Eshpeter; J Jiang; M Au; R V Rajotte; K Lu; J S Lebkowski; A S Majumdar; G S Korbutt
Journal:  Cell Prolif       Date:  2008-12       Impact factor: 6.831

5.  Crosstalk Between Activated Myofibroblasts and β Cells in Injured Mouse Pancreas.

Authors:  Jennifer-Ann Bayan; Zhechu Peng; Ni Zeng; Lina He; Jingyu Chen; Bangyan L Stiles
Journal:  Pancreas       Date:  2015-10       Impact factor: 3.327

6.  Adult-onset deletion of Pten increases islet mass and beta cell proliferation in mice.

Authors:  Kai-Ting Yang; Jennifer-Ann Bayan; Ni Zeng; Richa Aggarwal; Lina He; Zhechu Peng; Anketse Kassa; Melissa Kim; Zhiou Luo; Zhenrong Shi; Vivian Medina; Keerthi Boddupally; Bangyan L Stiles
Journal:  Diabetologia       Date:  2013-10-26       Impact factor: 10.122

7.  Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail.

Authors:  Daniella Brasacchio; Jun Okabe; Christos Tikellis; Aneta Balcerczyk; Prince George; Emma K Baker; Anna C Calkin; Michael Brownlee; Mark E Cooper; Assam El-Osta
Journal:  Diabetes       Date:  2009-02-10       Impact factor: 9.461

8.  Global Deletion of the Prolactin Receptor Aggravates Streptozotocin-Induced Diabetes in Mice.

Authors:  Gabriela Ramirez-Hernandez; Elva Adan-Castro; Nundehui Diaz-Lezama; Xarubet Ruiz-Herrera; Gonzalo Martinez de la Escalera; Yazmin Macotela; Carmen Clapp
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-05       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.